Last 7 days
5.0%
Last 30 days
12.9%
Last 90 days
13.7%
Trailing 12 Months
73.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 442.1B | 96.0B | -4.77% | 1.21% | 23.08 | 4.6 | 5.02% | 7.14% |
LLY | 308.1B | 29.2B | -6.33% | 46.49% | 51.07 | 10.54 | 5.34% | 1.02% |
MRK | 267.0B | 59.0B | -5.13% | 34.98% | 17.49 | 4.53 | 27.84% | 112.03% |
PFE | 245.5B | 99.9B | -13.80% | -15.92% | 8.25 | 2.46 | 45.01% | 53.21% |
BMY | 154.0B | 46.7B | 0.64% | 15.96% | 23.07 | 3.3 | 2.79% | 223.53% |
MID-CAP | ||||||||
PRGO | 5.0B | 4.4B | 10.03% | -0.57% | -46.66 | 1.14 | 1.80% | 57.67% |
SUPN | 2.2B | 659.0M | 13.79% | 40.18% | 57.51 | 3.29 | 16.78% | -53.92% |
SMALL-CAP | ||||||||
TLRY | 1.9B | 613.6M | 24.42% | -38.51% | -3.79 | 3.14 | 37.73% | -7.19% |
RETA | 1.6B | 3.1M | 23.90% | 79.89% | -5.08 | 503.44 | -77.09% | -12.24% |
CGC | 1.4B | - | 33.79% | -57.23% | -0.46 | 1.95 | -4.11% | -144.36% |
ACRS | 1.2B | 23.5M | 12.85% | 73.07% | -14.2 | 49.6 | 243.57% | -1.04% |
CRON | 942.1M | 112.7M | - | -24.55% | -4.21 | 8.36 | 45.53% | 40.26% |
INVA | 885.5M | - | -2.61% | -19.99% | 2.65 | 2.34 | 10.49% | -16.07% |
OCUL | 298.8M | 49.7M | 46.97% | -25.95% | -5.03 | 6.01 | 28.95% | 32.80% |
ENDP | 94.1M | 2.6B | -43.99% | -88.43% | -0.03 | 0.04 | -13.88% | -4855.92% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | 282.7% | 23,500,000 | 6,141,000 | 6,437,000 | 6,761,000 | 6,840,000 |
S&GA Expenses | -0.7% | 24,930,000 | 25,096,000 | 24,891,000 | 23,619,000 | 21,574,000 |
R&D Expenses | 15.8% | 70,843,000 | 61,163,000 | 50,281,000 | 43,813,000 | 38,667,000 |
EBITDA | 0.0% | -90,063,000.00 | -90,022,000.00 | - | - | - |
EBITDA Margin | -4.9% | -14.67 | -13.99 | - | - | - |
Earnings Before Taxes | - | -90,865,000.00 | - | - | - | - |
EBT Margin | -4.8% | -14.80 | -14.12 | - | - | - |
Net Income | 1.4% | -82,077,000.00 | -83,271,000.00 | -80,900,000.00 | -90,865,000.00 | -81,234,000.00 |
Net Income Margin | 74.2% | -3.49 | -13.56 | -12.57 | -13.44 | - |
Free Cahsflow | 3.9% | -66,227,000.00 | -68,922,000.00 | -61,431,000.00 | -52,442,000.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -3.7% | 268 | 278 | 227 | 251 | 263 |
Current Assets | -1.1% | 257 | 259 | 191 | 205 | 206 |
Cash Equivalents | -9.7% | 62 | 68 | 36 | 27 | 54 |
Net PPE | -10.3% | 1 | 1 | 1 | 1 | 1 |
Liabilities | 13.2% | 48 | 42 | 46 | 54 | 47 |
Current Liabilities | 22.0% | 20 | 16 | 17 | 23 | 18 |
Shareholder's Equity | -6.8% | 220 | 236 | 180 | 197 | 217 |
Retained Earnings | -3.1% | -654.68 | -634.73 | -614.20 | -595.41 | -572.60 |
Additional Paid-In Capital | 0.5% | 876 | 872 | 795 | 793 | 789 |
Shares Outstanding | 0.0% | 67 | 67 | 62 | 61 | 61 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | 4.1% | -65.53 | -68.32 | -60.87 | -52.13 | -43.92 |
Share Based Compensation | 3.6% | 14 | 14 | 14 | 14 | 13 |
Cashflow From Investing | 102.0% | 1 | -38.14 | -62.39 | -167.63 | -160.76 |
Cashflow From Financing | 18.9% | 73 | 61 | 124 | 225 | 233 |
100%
100%
91.2%
Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.
-3.4%
-6.5%
130.4%
FIve years rolling returns for Aclaris Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-26 | STRS OHIO | added | 82.91 | 260,000 | 573,000 | -% |
2023-01-25 | Lindbrook Capital, LLC | reduced | -12.97 | -724 | 3,276 | -% |
2023-01-23 | Allspring Global Investments Holdings, LLC | reduced | -1.25 | -11,415 | 1,028,580 | -% |
2023-01-18 | Verition Fund Management LLC | added | 122.61 | 7,054,000 | 11,726,000 | 0.07% |
2023-01-12 | Assenagon Asset Management S.A. | unchanged | - | 2,000 | 3,070,000 | 0.01% |
2023-01-06 | MASSMUTUAL TRUST CO FSB/ADV | unchanged | - | - | 1,000 | -% |
2022-11-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | new | - | 850,000 | 850,000 | 0.01% |
2022-11-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 5.84 | 168,000 | 1,033,000 | -% |
2022-11-17 | Telemetry Investments, L.L.C. | sold off | -100 | -154,000 | - | -% |
2022-11-16 | BNP PARIBAS ARBITRAGE, SNC | added | 57.77 | 145,241 | 331,705 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Apr 25, 2022 | ra capital management, l.p. | 7.1% | 4,398,453 | SC 13G | |
Feb 15, 2022 | rock springs capital management lp | 6.31% | 3,861,347 | SC 13G/A | |
Feb 14, 2022 | venrock healthcare capital partners ii, l.p. | 7.5% | 4,563,962 | SC 13G | |
Feb 11, 2022 | foresite capital fund iii, l.p. | 0.0% | 0 | SC 13G/A | |
Feb 04, 2022 | blackrock inc. | 6.7% | 4,078,875 | SC 13G | |
Feb 04, 2022 | wellington management group llp | 9.05% | 5,539,268 | SC 13G | |
Jan 24, 2022 | biotechnology value fund l p | 3.4% | 2,093,085 | SC 13G | |
Feb 16, 2021 | rock springs capital management lp | 6.24% | 2,676,100 | SC 13G/A | |
Feb 12, 2021 | ecor1 capital, llc | 3.5% | 1,509,812 | SC 13G/A | |
Feb 11, 2021 | adage capital partners gp, l.l.c. | 5.24% | 2,250,000 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jan 20, 2023 | 4 | Insider Trading | |
Jan 09, 2023 | 8-K | Current Report | |
Jan 06, 2023 | 3 | Insider Trading | |
Jan 06, 2023 | 8-K | Current Report | |
Jan 04, 2023 | 4 | Insider Trading | |
Dec 16, 2022 | 4 | Insider Trading | |
Dec 13, 2022 | 8-K | Current Report | |
Nov 22, 2022 | 8-K | Current Report | |
Nov 14, 2022 | 4 | Insider Trading | |
Nov 08, 2022 | 10-Q | Quarterly Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-04 | Walker Neal | sold | -223,342 | 14.8895 | -15,000 | - |
2023-01-03 | Walker Neal | sold | -381,213 | 15.2485 | -25,000 | - |
2022-12-15 | Monahan Joseph | sold | -79,411.5 | 15.8823 | -5,000 | chief scientific officer |
2022-11-14 | SCHIFF ANDREW N | sold | -23,416.7 | 17.08 | -1,371 | - |
2022-11-11 | SCHIFF ANDREW N | sold | -702,177 | 17.0597 | -41,160 | - |
2022-11-10 | SCHIFF ANDREW N | sold | -193,995 | 17.0246 | -11,395 | - |
2022-11-08 | Powell Andrew Kenneth William | gifted | - | - | -4,000 | - |
2022-10-26 | SCHIFF ANDREW N | sold | -247,253 | 17.005 | -14,540 | - |
2022-10-25 | SCHIFF ANDREW N | sold | -204,516 | 17.0175 | -12,018 | - |
2022-10-24 | SCHIFF ANDREW N | sold | -248,586 | 17.0078 | -14,616 | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Total revenue | $ 19,018 | $ 1,659 | $ 21,999 | $ 5,260 |
Costs and expenses: | ||||
Cost of revenue | 923 | 1,099 | 3,146 | 3,564 |
Research and development expense | 23,656 | 13,976 | 56,741 | 29,711 |
General and administrative expense | 5,813 | 5,979 | 17,987 | 16,676 |
Licensing | 7,300 | 7,300 | ||
Revaluation of contingent consideration | 2,200 | 900 | (2,400) | 22,139 |
Total costs and expenses | 39,892 | 21,954 | 82,774 | 72,090 |
Loss from operations | (20,874) | (20,295) | (60,775) | (66,830) |
Other income (expense), net | 922 | (851) | 1,502 | (1,231) |
Net loss | $ (19,952) | $ (21,146) | $ (59,273) | $ (68,061) |
Net loss per share, basic | $ (0.30) | $ (0.35) | $ (0.92) | $ (1.23) |
Net loss per share, diluted | $ (0.30) | $ (0.35) | $ (0.92) | $ (1.23) |
Weighted average common shares outstanding, basic | 66,675,337 | 61,219,321 | 64,718,008 | 55,215,037 |
Weighted average common shares outstanding, diluted | 66,675,337 | 61,219,321 | 64,718,008 | 55,215,037 |
Other comprehensive (loss) income: | ||||
Unrealized gain (loss) on marketable securities, net of tax of $0 | $ (139) | $ 5 | $ (1,241) | $ (5) |
Foreign currency translation adjustment | 176 | 96 | ||
Total other comprehensive (loss) income | (139) | 181 | (1,241) | 91 |
Comprehensive loss | (20,091) | (20,965) | (60,514) | (67,970) |
Contract research | ||||
Revenues: | ||||
Total revenue | 1,090 | 1,415 | 3,529 | 4,556 |
Licensing | ||||
Revenues: | ||||
Total revenue | 17,898 | 214 | 18,378 | 612 |
Other | ||||
Revenues: | ||||
Total revenue | $ 30 | $ 30 | $ 92 | $ 92 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 61,653 | $ 27,349 |
Short-term marketable securities | 186,409 | 164,065 |
Accounts receivable, net | 597 | 623 |
Prepaid expenses and other current assets | 7,914 | 12,995 |
Total current assets | 256,573 | 205,032 |
Marketable securities | 34,242 | |
Property and equipment, net | 1,145 | 1,335 |
Intangible assets | 6,992 | 7,048 |
Other assets | 2,922 | 3,554 |
Total assets | 267,632 | 251,211 |
Current liabilities: | ||
Accounts payable | 7,667 | 9,985 |
Accrued expenses | 9,154 | 10,051 |
Current portion of lease liabilities | 766 | 693 |
Discontinued operations | 2,202 | 2,202 |
Total current liabilities | 19,789 | 22,931 |
Other liabilities | 1,638 | 2,172 |
Contingent consideration | 26,000 | 28,400 |
Deferred tax liability | 367 | 367 |
Total liabilities | 47,794 | 53,870 |
Commitments and contingencies (Note 16) | ||
Stockholders' Equity: | ||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021 | ||
Common stock, $0.00001 par value; 100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 66,679,641 and 61,228,446 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | 1 | 1 |
Additional paid-in capital | 875,982 | 792,971 |
Accumulated other comprehensive loss | (1,465) | (224) |
Accumulated deficit | (654,680) | (595,407) |
Total stockholders' equity | 219,838 | 197,341 |
Total liabilities and stockholders' equity | $ 267,632 | $ 251,211 |